Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Prognostic implications of measurable residual disease and autologous hematopoietic stem cell transplantation in primary plasma cell leukemia in the era of novel agents

View Full Paper
Ask AI
Bookmark
Share

Authors

JDJingjing DengPWPing WangYTYing Tian

Discussion

Loading...

Member takes

Overview

Cohort study identifies MRD negativity and ASCT as key factors influencing survival in primary plasma cell leukemia.

Key Points

  • This study aims to evaluate the prognostic impact of minimal residual disease and autologous hematopoietic stem cell transplantation in primary plasma cell leukemia.
  • Conducted a retrospective cohort study at a single center (Beijing Chaoyang Hospital) from 2017 to 2024.
  • Assessed MRD using next-generation flow cytometry on bone marrow aspirates.
  • Analyzed survival outcomes using univariate/multivariate Cox regression and Kaplan-Meier methods.
  • MRD negativity was linked to improved overall survival and progression-free survival.
  • Median OS for ASCT cohort was significantly longer at 56.9 months versus 16.7 months for non-ASCT group.
  • 13 out of 17 patients experienced deeper remission post-ASCT, with 12 achieving MRD-negative status.

Cite This Study

Deng et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4d2https://doi.org/10.1182/blood-2025-7564
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patterns of progression and clinical outcomes after first relapse in patients with primary plasma cell leukemia2025 · 1 citations
  2. 2The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 study2026
  3. 3Outcomes of pPCL Diagnosed Using the IMWG 2021 Consensus Definition: A Retrospective Multicenter Analysis2026
  4. 4Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients2026
  5. 5Plasma cell leukemia: A single institution review of cases2025